| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
|
N Engl J Med
|
2014
|
9.09
|
|
2
|
Genome-wide association study identifies five susceptibility loci for glioma.
|
Nat Genet
|
2009
|
7.62
|
|
3
|
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
|
Lancet Oncol
|
2012
|
5.71
|
|
4
|
Detectable clonal mosaicism and its relationship to aging and cancer.
|
Nat Genet
|
2012
|
3.69
|
|
5
|
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
|
J Clin Oncol
|
2012
|
2.45
|
|
6
|
Breast cancer survival is associated with telomere length in peripheral blood cells.
|
Cancer Res
|
2008
|
2.24
|
|
7
|
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.
|
EMBO J
|
2004
|
2.20
|
|
8
|
Polymorphisms associated with asthma are inversely related to glioblastoma multiforme.
|
Cancer Res
|
2005
|
2.11
|
|
9
|
Genome-wide association study of glioma and meta-analysis.
|
Hum Genet
|
2012
|
1.96
|
|
10
|
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.
|
PLoS Genet
|
2010
|
1.74
|
|
11
|
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.
|
Clin Cancer Res
|
2005
|
1.66
|
|
12
|
Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.
|
Acta Neuropathol
|
2004
|
1.46
|
|
13
|
Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines.
|
Cancer Biol Ther
|
2006
|
1.46
|
|
14
|
Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.
|
Carcinogenesis
|
2008
|
1.45
|
|
15
|
LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?
|
Eur J Cancer
|
2007
|
1.44
|
|
16
|
Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?
|
Acta Oncol
|
2002
|
1.34
|
|
17
|
Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis.
|
J Neurooncol
|
2003
|
1.31
|
|
18
|
Comprehensive analysis of DNA repair gene variants and risk of meningioma.
|
J Natl Cancer Inst
|
2008
|
1.30
|
|
19
|
Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients.
|
Int J Cancer
|
2003
|
1.21
|
|
20
|
Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma.
|
Hum Mol Genet
|
2007
|
1.19
|
|
21
|
LRIG1 protein in human cells and tissues.
|
Cell Tissue Res
|
2003
|
1.18
|
|
22
|
The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea.
|
Genomics
|
2004
|
1.17
|
|
23
|
Dysregulated secretoglobin expression in human lung cancers.
|
Lung Cancer
|
2003
|
1.17
|
|
24
|
A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk.
|
Acta Oncol
|
2010
|
1.17
|
|
25
|
Common variation at 10p12.31 near MLLT10 influences meningioma risk.
|
Nat Genet
|
2011
|
1.12
|
|
26
|
Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
|
Acta Neuropathol
|
2006
|
1.10
|
|
27
|
An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.09
|
|
28
|
LRIG1 expression in colorectal cancer.
|
Acta Oncol
|
2007
|
1.08
|
|
29
|
Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden.
|
J Neurooncol
|
2003
|
1.05
|
|
30
|
Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium.
|
Cancer Res
|
2011
|
1.05
|
|
31
|
Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival.
|
Neuropathology
|
2009
|
1.05
|
|
32
|
Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.04
|
|
33
|
Characterization and tissue-specific expression of human LRIG2.
|
Gene
|
2004
|
1.04
|
|
34
|
The common D302H variant of CASP8 is associated with risk of glioma.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.02
|
|
35
|
LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer.
|
Int J Cancer
|
2011
|
1.01
|
|
36
|
ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases.
|
Anticancer Res
|
2009
|
1.01
|
|
37
|
Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.
|
Eur J Cancer
|
2009
|
1.00
|
|
38
|
Different aetiology of familial low-grade and high-grade glioma? A nationwide cohort study of familial glioma.
|
Neuroepidemiology
|
2002
|
0.99
|
|
39
|
LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix.
|
Acta Oncol
|
2010
|
0.99
|
|
40
|
Functional polymorphisms in folate metabolism genes influence the risk of meningioma and glioma.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.97
|
|
41
|
Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma.
|
J Neurooncol
|
2006
|
0.97
|
|
42
|
Increased copy number at 3p14 in breast cancer.
|
Breast Cancer Res
|
2005
|
0.97
|
|
43
|
MNS16A minisatellite genotypes in relation to risk of glioma and meningioma and to glioblastoma outcome.
|
Int J Cancer
|
2009
|
0.97
|
|
44
|
Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
|
Acta Oncol
|
2011
|
0.97
|
|
45
|
Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma.
|
Int J Oncol
|
2012
|
0.96
|
|
46
|
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.
|
Clin Breast Cancer
|
2003
|
0.95
|
|
47
|
An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.95
|
|
48
|
Pharmacological modulation of lung cancer cells for potassium ion depletion.
|
Anticancer Res
|
2005
|
0.92
|
|
49
|
Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.
|
Breast Cancer Res Treat
|
2011
|
0.92
|
|
50
|
Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
|
Exp Cell Res
|
2010
|
0.92
|
|
51
|
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
|
Breast Cancer Res Treat
|
2007
|
0.92
|
|
52
|
Lrig2-deficient mice are protected against PDGFB-induced glioma.
|
PLoS One
|
2013
|
0.91
|
|
53
|
Hypofractionated conformal stereotactic radiotherapy for arteriovenous malformations.
|
Neurosurgery
|
2003
|
0.91
|
|
54
|
Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy.
|
J Neurooncol
|
2008
|
0.89
|
|
55
|
Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study.
|
J Neurooncol
|
2005
|
0.89
|
|
56
|
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
|
J Neurooncol
|
2008
|
0.89
|
|
57
|
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
|
Anticancer Res
|
2012
|
0.89
|
|
58
|
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
|
Eur J Haematol
|
2008
|
0.89
|
|
59
|
Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats.
|
Prostate
|
2007
|
0.89
|
|
60
|
p53 Genotypes and risk of glioma and meningioma.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.89
|
|
61
|
Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma.
|
BMC Res Notes
|
2012
|
0.88
|
|
62
|
Known glioma risk loci are associated with glioma with a family history of brain tumours -- a case-control gene association study.
|
Int J Cancer
|
2012
|
0.88
|
|
63
|
Mammaglobin in normal human sweat glands and human sweat gland tumors.
|
J Invest Dermatol
|
2003
|
0.88
|
|
64
|
ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family.
|
Acta Oncol
|
2004
|
0.88
|
|
65
|
A specialist nurse as a resource for family members to patients with brain tumors: an action research study.
|
Cancer Nurs
|
2008
|
0.87
|
|
66
|
Genetic variations in EGF and EGFR and glioblastoma outcome.
|
Neuro Oncol
|
2010
|
0.87
|
|
67
|
Metabolic manipulation of glioblastoma in vivo by retrograde microdialysis of L-2, 4 diaminobutyric acid (DAB).
|
J Neurooncol
|
2006
|
0.87
|
|
68
|
LRIG and cancer prognosis.
|
Acta Oncol
|
2014
|
0.87
|
|
69
|
[Registration on regional basis of patients with primary brain tumors. Regional differences disclosed].
|
Lakartidningen
|
2007
|
0.86
|
|
70
|
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
|
Clin Cancer Res
|
2006
|
0.86
|
|
71
|
Association between adult height, genetic susceptibility and risk of glioma.
|
Int J Epidemiol
|
2012
|
0.86
|
|
72
|
Brain tumors in Sweden: data from a population-based registry 1999-2012.
|
Acta Oncol
|
2014
|
0.86
|
|
73
|
EGFR gene variants are associated with specific somatic aberrations in glioma.
|
PLoS One
|
2012
|
0.86
|
|
74
|
Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.85
|
|
75
|
Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome.
|
Breast Cancer Res Treat
|
2011
|
0.85
|
|
76
|
Secretoglobins in the human pituitary: high expression of lipophilin B and its down-regulation in pituitary adenomas.
|
Acta Neuropathol
|
2005
|
0.84
|
|
77
|
Severely diseased lung cancer patients narrate the importance of being included in a helping relationship.
|
Lung Cancer
|
2005
|
0.84
|
|
78
|
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
|
Anticancer Res
|
2012
|
0.84
|
|
79
|
Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.
|
Med Oncol
|
2012
|
0.84
|
|
80
|
DNA-repair gene variants are associated with glioblastoma survival.
|
Acta Oncol
|
2011
|
0.83
|
|
81
|
Acquisition of cisplatin-resistance in malignant mesothelioma cells abrogates Na+,K+,2Cl(-)-cotransport activity and cisplatin-induced early membrane blebbing.
|
Cell Physiol Biochem
|
2008
|
0.83
|
|
82
|
Spatial expression of VEGF-A in human glioma.
|
J Neurooncol
|
2002
|
0.83
|
|
83
|
Redistribution of LRIG proteins in psoriasis.
|
J Invest Dermatol
|
2007
|
0.83
|
|
84
|
Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation.
|
Anticancer Res
|
2008
|
0.82
|
|
85
|
Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer.
|
Eur J Cancer
|
2011
|
0.82
|
|
86
|
Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer.
|
Breast Cancer Res
|
2009
|
0.81
|
|
87
|
CASP8 D302H and meningioma risk: an analysis of five case-control series.
|
Cancer Lett
|
2008
|
0.80
|
|
88
|
LRIG1 is a prognostic biomarker in non-small cell lung cancer.
|
Acta Oncol
|
2015
|
0.80
|
|
89
|
Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies.
|
Anticancer Res
|
2007
|
0.80
|
|
90
|
[Free of charge mammography gets more people to the examination. Study in Stockholm County shows good efficacy in socioeconomically disadvantaged areas].
|
Lakartidningen
|
2014
|
0.80
|
|
91
|
Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate.
|
J Cancer Res Clin Oncol
|
2002
|
0.79
|
|
92
|
Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
|
Acta Oncol
|
2009
|
0.79
|
|
93
|
Daily-diary evaluated side effects of dose-escalation radiotherapy of prostate cancer using the stereotactic BeamCath technique.
|
Acta Oncol
|
2003
|
0.79
|
|
94
|
Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival.
|
Breast Cancer Res Treat
|
2011
|
0.78
|
|
95
|
Reproducibility and geometric accuracy of the Fixster system during hypofractionated stereotactic radiotherapy.
|
Radiat Oncol
|
2008
|
0.78
|
|
96
|
Analysis of DNA repair gene polymorphisms and survival in low-grade and anaplastic gliomas.
|
J Neurooncol
|
2011
|
0.78
|
|
97
|
The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer.
|
Med Oncol
|
2012
|
0.78
|
|
98
|
Induction of apoptosis in resistant glioma cells by synthetic caspase-activation.
|
J Neurooncol
|
2004
|
0.78
|
|
99
|
Cellular potassium ion deprivation enhances apoptosis induced by cisplatin.
|
Basic Clin Pharmacol Toxicol
|
2004
|
0.77
|
|
100
|
The creation of hope in patients with lung cancer.
|
Acta Oncol
|
2014
|
0.77
|
|
101
|
Adenylate cyclase toxin from Bordetella pertussis enhances cisplatin-induced apoptosis to lung cancer cells in vitro.
|
Oncol Res
|
2006
|
0.77
|
|
102
|
A specialist nurse-function in neurooncology: a qualitative study of possibilities, limitations, and pitfalls.
|
Palliat Support Care
|
2005
|
0.77
|
|
103
|
Single nucleotide polymorphisms in the DMBT1 promoter and the progression of breast cancer.
|
Int J Cancer
|
2007
|
0.76
|
|
104
|
Considerable improvement in survival for patients aged 60-84 years with high grade malignant gliomas -- data from the Swedish Brain Tumour Population-based Registry.
|
Acta Oncol
|
2013
|
0.76
|
|
105
|
The antimicrotubule drug estramustine but not irradiation induces apoptosis in malignant glioma involving AKT and caspase pathways.
|
J Neurooncol
|
2002
|
0.76
|
|
106
|
Does a low frequency of P53 and Pgp expression in familial glioma compared to sporadic controls indicate biological differences?
|
Anticancer Res
|
2003
|
0.76
|
|
107
|
Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
|
Acta Oncol
|
2012
|
0.76
|
|
108
|
[In Process Citation].
|
Lakartidningen
|
2015
|
0.75
|
|
109
|
It is now time for a powerful view in the management of lung cancer.
|
Acta Oncol
|
2002
|
0.75
|
|
110
|
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.
|
Int J Oncol
|
2010
|
0.75
|
|
111
|
Novel agents in the treatment of non-small cell lung cancer: implications for neoadjuvant chemotherapy?
|
In Vivo
|
2005
|
0.75
|
|
112
|
[Survival in malignant gliomas has increased the last decade. Analysis of quality data].
|
Lakartidningen
|
2012
|
0.75
|
|
113
|
The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy.
|
Anticancer Res
|
2012
|
0.75
|
|
114
|
Swedish Lung Cancer Radiation Study Group: predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancer.
|
Acta Oncol
|
2012
|
0.75
|
|
115
|
Phase-contrast microscopy studies of early cisplatin-induced morphological changes of malignant mesothelioma cells and the correspondence to induced apoptosis.
|
Exp Lung Res
|
2008
|
0.75
|
|
116
|
Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
|
Melanoma Res
|
2003
|
0.75
|